Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.

Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Abstract Text:

The purpose of this study was to examine the relationship between the degree of anxiety or somatic symptoms present before treatment with the subsequent diagnosis of treatment-related adverse events (TRAEs) in patients with major depressive disorder (MDD) enrolled in an 8-week open trial of fluoxetine (20 mg). Baseline symptom questionnaires (SQ) were completed by 170 MDD patients enrolled in the trial. We then tested whether pre-treatment scores for anxiety and somatic symptoms predicted (1) whether patients were subsequently diagnosed with TRAEs; (2) whether they were subsequently diagnosed with moderate or severe TRAEs; or (3) whether a greater number of TRAEs were diagnosed during the trial. We found that depressed patients who presented with prominent somatic symptoms were significantly more likely to report at least one moderate or severe side effect during the course of treatment, but not more likely to report a greater number of side effects. Pre-treatment anxiety was not related to the development of side effects.

Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Publishing Authors By Initials

For similar mental disorders: somatoform disorders research abstracts see: mental disorders: somatoform disorders research

PUBMED ID PMID:

MEDLINE DATE:

Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Psychiatry research

VOLUME: 126

Page Numbers: 287-90

Journal Abbreviation: Psychiatry Res

ISSN: 0165-1781

DAY: 30

MONTH: May

YEAR: 2004

Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7911385

Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Keywords Mesh Terms:

KEYWORDS: Somatoform Disorders

MESH TERMS: psychology

Chemical & Substance for Abstract: Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Information

Substance Name: Fluoxetine

Registry Number: 54910-89-3

Grant and Affiliation Information for Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.

AFFILIATION: Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC 812, Boston, MA 02114, USA. gpapakostas@partners.org

Country: Ireland

AGENCY: United States NIMH

GRANT: R01-MH-48-483-05

ACRONYM: MH

MEDLINETA: Psychiatry Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder Related Publications

• A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
• Acupuncture for major depressive disorder: has its efficacy been disproved?
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
• Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression.
• Antidepressant dose reduction and the risk of relapse in major depressive disorder.
• Augmenting antidepressants with folate: a clinical perspective.
• Bond strength of adhesive systems to human tooth enamel.
• Cat posture on a tilted platform.
• Comparison of quality of life measures in a depressed population.
• Delayed bezafibrate-induced angio-oedema in a 68-year-old man.
• Differential Antidepressant Symptom Efficacy: Placebo-Controlled Comparisons of Duloxetine and SSRIs (Fluoxetine, Paroxetine, Escitalopram).
• Financial conflicts of interest in psychiatry.
• Low-Income HIV-Infected Women and the Process of Engaging in Healthy Behavior.
• Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis.
• Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study.
• Major depressive disorder with anger attacks and cardiovascular risk factors.
• Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities.
• Pain in depression: STAR*D study findings.
• Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study.
• Preadult onset vs. adult onset of major depressive disorder: a replication study.
• Psychosocial impairment in patients treated for pituitary disease: a controlled study.
• Recognizing and engaging depressed Chinese Americans in treatment in a primary care setting.
• Rehabilitation in endocrine patients: a novel psychosomatic approach.
• SUNCT and high nocturnal prolactin levels: some new unusual characteristics.
• Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine.
• The STAR*D study: treating depression in the real world.
• The utility of non-proportional quota sampling for recruiting at-risk women for microbicide research.
• Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
• Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.
• Validation of the Patient Health Questionnaire-9 for depression screening among Chinese Americans.